Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
telatinib + capecitabine + oxaliplatin
- Development stage
- Phase 2
- Lead developer
- Taizhou EOC Pharma
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**Telatinib + capecitabine + oxaliplatin** is an investigational combination therapy evaluated as a first-line treatment for HER2-negative advanced adenocarcinoma of the stomach or gastroesophageal junction. - **Telatinib** is an oral small molecule inhibitor targeting vascular endothelial growth factor receptors (VEGFR-2, VEGFR-3), platelet-derived growth factor receptor beta (PDGFR-β), and c-Kit, thereby inhibiting angiogenesis. - **Capecitabine** is an oral prodrug converted to 5-fluorouracil (5-FU), which inhibits thymidylate synthase, disrupting DNA synthesis and exerting cytotoxic effects on rapidly dividing cells. - **Oxaliplatin** is a platinum-based chemotherapeutic agent that forms DNA crosslinks and promotes cell death in proliferating cells. The combination is designed to synergistically inhibit tumor growth and angiogenesis, combining targeted anti-angiogenic mechanisms (telatinib) with cytotoxic chemotherapy (capecitabine and oxaliplatin)[2][5][8].
- Other names
- XELOX plus telatinibCAPOX plus telatinib
02
Targets
DNAPDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)TS (Thymidylate synthase)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on telatinib + capecitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on telatinib + capecitabine + oxaliplatin.